[go: up one dir, main page]

ATE339957T1 - Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs - Google Patents

Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs

Info

Publication number
ATE339957T1
ATE339957T1 AT00973002T AT00973002T ATE339957T1 AT E339957 T1 ATE339957 T1 AT E339957T1 AT 00973002 T AT00973002 T AT 00973002T AT 00973002 T AT00973002 T AT 00973002T AT E339957 T1 ATE339957 T1 AT E339957T1
Authority
AT
Austria
Prior art keywords
breast cancer
tyrosine kinase
egfr tyrosine
kinase inhibitors
treat breast
Prior art date
Application number
AT00973002T
Other languages
English (en)
Inventor
Nigel James Bundred
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Application granted granted Critical
Publication of ATE339957T1 publication Critical patent/ATE339957T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00973002T 1999-11-02 2000-11-01 Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs ATE339957T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9925958.2A GB9925958D0 (en) 1999-11-02 1999-11-02 Therapeutic use

Publications (1)

Publication Number Publication Date
ATE339957T1 true ATE339957T1 (de) 2006-10-15

Family

ID=10863835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00973002T ATE339957T1 (de) 1999-11-02 2000-11-01 Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs

Country Status (21)

Country Link
US (1) US7553815B1 (de)
EP (1) EP1272188B1 (de)
JP (1) JP2003513035A (de)
KR (1) KR100785359B1 (de)
CN (1) CN1197577C (de)
AT (1) ATE339957T1 (de)
AU (1) AU779190B2 (de)
BR (1) BR0015194A (de)
CA (1) CA2389411C (de)
CY (1) CY1106285T1 (de)
DE (1) DE60030889T2 (de)
DK (1) DK1272188T3 (de)
ES (1) ES2275556T3 (de)
GB (1) GB9925958D0 (de)
IL (1) IL149176A0 (de)
MX (1) MXPA02004272A (de)
NO (1) NO323206B1 (de)
NZ (1) NZ518696A (de)
PT (1) PT1272188E (de)
WO (1) WO2001032155A2 (de)
ZA (1) ZA200203431B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
KR20130056201A (ko) 2000-05-19 2013-05-29 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
EP1408980A4 (de) 2001-06-21 2004-10-20 Ariad Pharma Inc Neue chinazoline und ihre verwendungszwecke
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20050038048A1 (en) * 2001-10-29 2005-02-17 Ball Howard Ashley Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases
PT2305255E (pt) * 2001-12-03 2012-09-04 Bayer Healthcare Llc Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
US7384940B2 (en) * 2002-06-05 2008-06-10 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
US20070059785A1 (en) * 2003-08-15 2007-03-15 Smithkline Beecham Corporation Biomarkers in cancer
BRPI0414532B1 (pt) 2003-09-19 2018-06-05 Astrazeneca Ab Composto derivado de quinazolina, processo para preparar 0 mesmo, composição farmaceutica, e, uso de um composto derivado de quinazolina
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7701341B2 (en) * 2004-09-01 2010-04-20 Microsoft Corporation Device service provider interface
KR20150083139A (ko) 2005-01-21 2015-07-16 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
DK1850874T3 (da) 2005-02-23 2013-11-11 Genentech Inc Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
CA2642665C (en) 2006-02-09 2013-01-08 Daiichi Sankyo Company, Limited Anti-cancer pharmaceutical composition
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
PL2132573T3 (pl) 2007-03-02 2014-09-30 Genentech Inc Prognozowanie odpowiedzi na inhibitor dimeryzacji HER oparte na niskiej ekspresji HER3
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2592156B1 (de) 2007-06-08 2016-04-20 Genentech, Inc. Genexpressionsmarker für Tumorresistenz gegen Behandlung mit HER2-Inhibitor
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2405908B1 (de) 2009-03-11 2016-12-21 Ardea Biosciences, Inc. Pharmazeutische kombination von rdea119/bay 869766 und gemcitabin für die behandlung von spezifischen krebserkrankungen
TW201438739A (zh) 2009-03-20 2014-10-16 Genentech Inc 抗-ｈｅｒ抗體
EP2435071A1 (de) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulatoren für den her2-signalweg bei her2-exprimierenden patienten mit magenkrebs
DK2536748T3 (da) 2010-02-18 2014-10-13 Genentech Inc Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (de) 2010-11-24 2013-10-02 Novartis AG Multispezifische moleküle
EP2655413B1 (de) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
CA2857114A1 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
CA2865082A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
ATE205483T1 (de) * 1995-03-30 2001-09-15 Pfizer Chinazolinderivate
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996040142A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
CN1100778C (zh) * 1995-07-06 2003-02-05 诺瓦蒂斯有限公司 吡咯并嘧啶及其制备方法
CZ20004224A3 (cs) * 1998-05-15 2002-02-13 Imclone Systems Incorporated Neradioaktivně značený inhibitor proteinového tyrosinkinázového receptoru
US20090202167A1 (en) 2006-08-28 2009-08-13 Koninklijke Philips Electronics N.V. Method and apparatus for image enhancement

Also Published As

Publication number Publication date
CY1106285T1 (el) 2011-10-12
DE60030889D1 (de) 2006-11-02
EP1272188A2 (de) 2003-01-08
IL149176A0 (en) 2002-11-10
CA2389411C (en) 2009-09-01
GB9925958D0 (en) 1999-12-29
DK1272188T3 (da) 2007-01-29
KR100785359B1 (ko) 2007-12-18
DE60030889T2 (de) 2007-04-05
NZ518696A (en) 2004-12-24
AU779190B2 (en) 2005-01-13
JP2003513035A (ja) 2003-04-08
NO20022065L (no) 2002-06-24
ES2275556T3 (es) 2007-06-16
WO2001032155A2 (en) 2001-05-10
KR20020064306A (ko) 2002-08-07
PT1272188E (pt) 2007-01-31
EP1272188B1 (de) 2006-09-20
CA2389411A1 (en) 2001-05-10
CN1387437A (zh) 2002-12-25
ZA200203431B (en) 2003-02-26
CN1197577C (zh) 2005-04-20
BR0015194A (pt) 2002-06-18
NO20022065D0 (no) 2002-04-30
US7553815B1 (en) 2009-06-30
NO323206B1 (no) 2007-01-22
WO2001032155A3 (en) 2002-05-10
MXPA02004272A (es) 2003-08-20
AU1155901A (en) 2001-05-14

Similar Documents

Publication Publication Date Title
ATE339957T1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE323474T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
MXPA00011248A (es) Tratamientos de tumores humanos con radiacion e inhibidores de tirosina cinasas de recptor de factor de crecimiento.
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
MY151032A (en) Treatment of tnf? related disorders
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
EP1231914A4 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE404202T1 (de) Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
TNSN04015A1 (en) Combination therapy for the treatment of cancer
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272188

Country of ref document: EP

REN Ceased due to non-payment of the annual fee